Table 5.

Examples of nanocarriers for anticancer therapy

Nanotechnology platform	Description	Pharmaceutical ingredients	Disease	Status	References
PNP	Decorated with somatostatin analogue	Cetuximab	Colon cancer	Phase 1	NCT03774680
NP	Combined with enzalutamide	Camptothecin	Metastatic castration resistant prostate cancer	Phase 2	NCT03531827
NP	Co-coated drug	Nab-paclitaxel rituximab	B-Cell Non-Hodgkin Lymphoma	Phase 1	NCT03003546
Liposome	Liposome	irinotecan	Small cell lung cancer	Phase 3	NCT03088813
Liposome	Pegylated liposomal carrier	Doxorubicin trastuzumab	HER2-positive metastatic breast cancer	Phase 2	NCT03933319
Nanoemulsion	Photosensitizer in PDT therapy	Aminolevulinic acid nanoemulsion	Basal cell carcinomas	Phase 2	NCT02367547
Quantum dot	Coated with drug	veldoreotide	Breast cancer	Phase 1	NCT04138342
Albumin NP	NP bound albumin (Abraxane)	Paclitaxel	Breast cancer, NSCLC, pancreatic cancer	Approved by FDA	[254]
Liposome	Liposome (DepoCyt)	Cytarabine	Lymphomatous malignancies	Approved by FDA	[255]
Liposome	Liposome (Marqibo)	Vincristine sulfate	Acute lymphoblastic leukemia	Approved by FDA	[256]
Liposome	Liposome (Doxil)	Doxorubicin	HIV-related Kaposi sarcoma, ovarian cancer, multiple myeloma	Approved by FDA	[19]
Liposome	Liposome (DaunoXome)	Daunorubicin	HIV-related Kaposi sarcoma	Approved by FDA	[257]
Polymer protein conjugate	Multi-agent chemotherapy-eutic regimen (Oncaspar)	L-asparaginase	leukemia	Approved by FDA	[258]

NP, nanoparticle; PDT, Photodynamic therapy; PNP, Polymeric nanoparticle

US Clinical trials website (http://clinicaltrials.gov/) [259]–US Food and Drug Administration website (http://www.accessdata.fda.gov/) [260]